Cargando…
Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy
OBJECTIVE: Genomic profiles relating to H101 treatment-induced alterations are yet to be achieved. Here, we evaluated the impact of H101 via exome-sequencing approaches aiming to probe for potential biomarkers that are actionable in the treatment of persistent/recurrent/metastatic (P/R/M) cervical c...
Autores principales: | Zhang, Qiying, Zhang, Jing, Liu, Zi, Wang, Juan, Wang, Fei, Wang, Tao, Shi, Fan, Su, Jin, Zhao, Yalong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691960/ https://www.ncbi.nlm.nih.gov/pubmed/38046281 http://dx.doi.org/10.2147/DDDT.S429180 |
Ejemplares similares
-
Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study
por: Zhang, Jing, et al.
Publicado: (2022) -
A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study
por: Zhang, Ran, et al.
Publicado: (2021) -
Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real‐world study
por: Wang, Baocheng, et al.
Publicado: (2023) -
Corrigendum: A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study
por: Zhang, Ran, et al.
Publicado: (2022) -
Oncolytic adenovirus H101 ameliorate the efficacy of anti‐PD‐1 monotherapy in colorectal cancer
por: Huang, Lili, et al.
Publicado: (2022)